Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin
- 1 March 2008
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 21 (3) , 207-217
Abstract
Cancer morbidity and mortality are increasingly apparent risks in transplant recipients, thus reducing life quality and overall survival. These risks have largely been attributed to long-term immunosuppressive drug therapy, which remains necessary to prevent organ allograft rejection. Interestingly, however, recent studies challenge the premise that all immunosuppressive drugs necessarily promote cancer. A particular class of immunosuppressants, referred to as mammalian target of rapamycin (mTOR) inhibitors, has been shown to have potent anti-cancer effects that are presently being tested in clinical studies. The focus of this review is to present current evidence that allows us to understand better the dual immunosuppressive and anti-cancer functions of this class of drugs used to prevent allograft rejection. We will concentrate on the different functions of mTOR that allow it to simultaneously control the immune system and tumor development. We will also discuss results from current clinical studies that either support or refute this potential dualistic role.Keywords
This publication has 82 references indexed in Scilit:
- Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell LymphomaThe American Journal of Pathology, 2006
- Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphomaLeukemia, 2006
- Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathwaysBiochemical and Biophysical Research Communications, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Cancers et immunosuppression : effet pro- et antitumoral des traitements immunosuppresseursNephrologie & Therapeutique, 2005
- The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 2005
- The Rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1Laboratory Investigation, 2004
- Skin Cancers after Organ TransplantationNew England Journal of Medicine, 2003
- Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumourJournal of Cancer Research and Clinical Oncology, 1997
- Cyclosporin a inhibits interleukin 2-dependent growth of alloactivated cloned human T-lymphocytesInternational Journal of Immunopharmacology, 1983